Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation

• Published in: International journal of artificial organs Vol. 20; no. 1; p. 18
• Main Authors: Lal, S M, Gupta, N, Georgiev, O, Ross, Jr, G
• Format: Journal Article
• Language: English
• Published: United States 01-01-1997
• Subjects: Adult; Aged; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - pharmacology; Anticholesteremic Agents - therapeutic use; Arteriosclerosis - blood; Arteriosclerosis - complications; Arteriosclerosis - drug therapy; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Diet; Drug Therapy, Combination; Fatty Acids, Monounsaturated - administration & dosage; Fatty Acids, Monounsaturated - pharmacology; Fatty Acids, Monounsaturated - therapeutic use; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents - therapeutic use; Indoles - administration & dosage; Indoles - pharmacology; Indoles - therapeutic use; Kidney Transplantation - adverse effects; Male; Middle Aged; Triglycerides - blood
• ISSN: 0391-3988
• DOI: 10.1177/039139889702000105

A Atherosclerosis-related cardiovascular disease remains an important cause of morbidity and mortality in renal transplant patients. We assessed the efficacy and safety of the newer synthetic HMG-CoA reductase inhibitor, fluvastatin, in 12 renal transplant patients who remained hypercholesterolemic, despite having been on the American Heart Association (AHA) Step I diet for 6 weeks. At 8 weeks, compared to the control phase, fluvastatin therapy, 20 mg/day, reduced the total cholesterol (TC) from 321 +/- 57 [+/-SD] to 301 +/- 123 mg/dl (p = 0.3); low-density lipoprotein cholesterol (LDL-C), from 209 +/- 56 to 176 +/- 81 mg/dl (p = 0.2); and the triglyceride (TG) levels from 343 +/- 119 to 277 +/- 117 mg/dl (p = 0.06); all these changes were statistically insignificant. However, the therapy significantly increased the high-density lipoprotein cholesterol (HDL-C) from 37 +/- 11 to 46 +/- 13 mg/dl (p = 0.006). During this short-term treatment period no adverse biochemical effects were noted with the therapy.